The LiveRNA project will use CRISPR-Cas13 technology to locate, track, and reduce the expression of transcripts of interest in order to investigate how transcriptomic modifications influence gene expression and cellular behavior. This will provide insights into the molecular mechanisms underlying colorectal cancer and enable the identification of potentially new and innovative therapeutic strategies.

With the expertise of our diaspora partner in CRISPR-Cas technology, and by studying the function of a target non-coding RNA transcript, this proof-of-concept approach could be extended to explore the roles of other non-coding transcripts as well.

The proposed project establishes a new collaboration between IMGGI researchers and a diaspora partner, fostering continuous mobility and the exchange of knowledge, expertise, and personnel, which will significantly enhance the research and human capacities of IMGGI. Additionally, through targeted workshops and seminars, we will strengthen the local scientific community and the next generation of researchers by equipping them with the latest advances in CRISPR-Cas technology and its applications. This partnership between Serbia and the diaspora reinforces international research connections, promotes cross-border collaboration, and provides access to global scientific networks—crucial factors for fostering innovation and advancing science.